newsfilter
← Latest News
ACCESS Newswire·

BioLargo Reports Third Quarter 2026 Results, Forecasting Commercial Breakout in 2027

  • BioLargo, Inc. reported Q3 2026 financial results with total revenue of $1,090,000, a 1% decrease from the prior year.
  • Net loss for the third quarter was $3,824,000, a 47% decrease from the same period in 2025.
  • Clyra Medical accounted for 57% of the nine-month consolidated net loss due to investments in personnel, manufacturing, product development, and clinical activities.
  • The company launched its "barebird" consumer brand featuring CupriDyne technology for pet and laundry odor control.
  • New distributors for Clyra Medical's ViaCLYR product include Advanced Solution (U.S.), Al-Hikma FZCO (international), and Spartan Medical (U.S. government).
  • BioLargo Engineering team revenue increased by 23% while supporting PFAS and Cellinity projects.
  • The Aqueous Electrostatic Concentrator (AEC) PFAS treatment technology is validated and operational in Lake Stockholm, New Jersey.
  • Annual Meeting of Stockholders is scheduled for December 1, 2026, in Aliso Viejo, California.
  • BioLargo will forgo a quarterly earnings call in favor of the Annual Meeting.
  • Total revenue for the first nine months of 2026 was $3,452,000, a 52% decrease from the prior year.
  • Net cash used in operating activities for the nine months was $8,182,000.
  • Clyra Medical raised $4,299,000 primarily through debt to fund operations.
  • A new product line for Clyra Medical is expected for a national rollout in 2027.
Company
BioLargo, Inc
Keywords
Chemicals, Earnings